Core Viewpoint - The company, Berry Genomics (000710), focuses on the reproductive health sector, achieving significant commercial effects in the prenatal testing market while the pre-pregnancy and newborn markets are still in the early stages, indicating substantial market potential [1] Group 1 - The company plans to expand its complex genetic testing services into more areas, leveraging artificial intelligence applications and years of experience in third-generation sequencing technology [1] - The company aims to provide more health services directly to the consumer (C-end) by integrating clinical medical data in the future [1] - The recent changes in major shareholder equity do not impact the company's business development [1]

贝瑞基因（000710.SZ）8月5日在投资者互动平台表示，公司业务一直聚焦生育健康领域，产前检测市 场已达成较好的商业效应，但在孕前和新生儿市场还处于起步阶段，市场空间较大。凭借人工智能应用 和公司积累多年的三代测序技术，公司将在更多领域开展复杂基因检测服务。同时，结合临床医疗数 据，后续公司计划将直接为C端群体提供更多健康服务。目前大股东股权变动不影响公司业务发展。 每经AI快讯，有投资者在投资者互动平台提问：董秘您好，公司信用减值损失连续几年上亿元，面对 主业持续亏损的情况下，请问公司如何解决当前困境，是否谋划扩展新业务来实现高质量发展？还有公 司大股东股权接连遭司法拍卖，公司有无应对措施，公司的控制权会不会发生变化？ （文章来源：每日经济新闻） ...